Inside Colossal’s Dallas Headquarters Powering Its Woolly Mammoth Revival Effort

Colossal Biosciences’ Dallas headquarters was recently profiled by D Magazine, offering a rare glimpse inside the secured facility where the company’s woolly mammoth program, dire wolf research, dodo, and moa initiatives are underway.

According to reporting by Layten Praytor, the 55,000-square-foot laboratory consolidates Colossal’s gene-editing, reproductive biology, and genomic preservation research under one roof. For years, the location remained private, but D Magazine was granted limited access to observe scientists advancing multiplex genome editing, somatic cell nuclear transfer (SCNT), and assisted reproductive technologies.

The facility serves as the operational hub behind Colossal’s broader de-extinction and conservation initiatives. In 2025, the company became the first Texas-based startup to reach a $10 billion valuation, reflecting rapid growth across its biotechnology platform and global conservation partnerships.

Founder and CEO Ben Lamm told D Magazine that Colossal’s next major milestone is its woolly mammoth revival effort, currently targeting 2028, pending continued scientific progress and broader alignment around research standards tied to elephant-derived genomic data.

The article also revisits Colossal’s 2024 announcement of three genetically engineered canids designed to reintroduce key traits associated with the extinct dire wolf. The animals remain in secured, managed environments under strict animal welfare and oversight protocols, with ongoing monitoring and review.

D Magazine reports that Colossal plans to expand the Dallas headquarters by an additional 30,000 square feet to support avian research tied to its dodo and moa initiatives, as well as robotic process automation intended to increase efficiency in high-volume cloning workflows.

Over the past year, Colossal has also:

• Raised $120 million to support avian species initiatives

• Doubled nonprofit commitments to $50 million

• Acquired cloning and biobanking firm Viagen

• Expanded international conservation partnerships

The Dallas headquarters represents a consolidation of Colossal’s conservation genetics, advanced reproductive technologies, and computational genomics capabilities — infrastructure the company says will support both functional de-extinction and endangered species genetic rescue.

Why this matters

• Demonstrates physical infrastructure behind woolly mammoth revival efforts

• Reinforces Colossal’s $10B valuation and Texas biotech leadership

• Highlights ongoing gene-editing and assisted reproductive breakthroughs

• Signals expansion of conservation biotechnology capacity

Source: D Magazine reporting by Layten Praytor (February 17, 2026).